DFE Pharma, a global leader in pharmaceutical excipient solutions, has a new addition to its excipient portfolio, Pharmacel® sMCC 90, a silicified microcrystalline cellulose (MCC). Pharmacel® sMCC 90 has been developed as the synergistic solution for challenging oral solid dosage formulations.
Co-processed excipients are gaining popularity as they offer effective means to rapidly develop products for early human trials, while minimizing the risk to product quality. Pharmacel® sMCC 90 is the latest introduction within DFE Pharma’s MCC co-processed portfolio. Co-processing silicon dioxide with microcrystalline cellulose increases its surface area, resulting in enhanced powder flow, superior tabletability, thus providing formulation robustness. This silicified microcrystalline cellulose has been developed as the synergistic solution for challenging formulations.
Bas van Driel, CEO of DFE Pharma, commented: “Pharmacel® sMCC 90 is an ideal excipient that improves tablet compression and aids higher production speed, thereby enabling rapid formulation development. We always put innovation at the heart of our business, thereby bringing excipients with multiple functionality benefits to our customers to meet their formulation needs.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!